Latest news with #ASMB
Business Insider
5 days ago
- Business
- Business Insider
Assembly Biosciences presents Phase 1a data for ABI-5366, ABI-1179
Assembly Biosciences (ASMB) announced Phase 1a clinical and preclinical data for its herpes simplex virus, HSV, helicase-primase inhibitor candidates ABI-5366 and ABI-1179 are featured in multiple poster presentations, including one late-breaker, during the STI & HIV 2025 World Congress, taking place July 26-30, 2025, in Montreal, Canada, as well as in oral and poster presentations at the 49th Annual International Herpesvirus Workshop, taking place July 26-30, 2025, in Berlin, Germany. At the STI & HIV 2025 World Congress, two posters highlight the safety and pharmacokinetic profiles of ABI-5366 and ABI-1179 as observed in healthy participants in Phase 1a studies, supporting their progression to Phase 1b evaluation. The late-breaking poster for ABI-1179, the first scientific presentation of Phase 1a clinical data for this candidate, includes additional new interim data showing that, as was also the case in the ABI-5366 Phase 1a study, no clinically significant food effect was observed. Unblinded safety data for ABI-1179 are also included in this presentation. Elevate Your Investing Strategy:
Yahoo
03-07-2025
- Business
- Yahoo
Assembly Biosciences, Inc. (ASMB) Announces Key Leadership and Plan Changes
Assembly Biosciences, Inc. (NASDAQ:ASMB) is among the best growth stocks to invest in for the next 5 years. In the wake of its recent Annual Meeting of Stockholders, Assembly Biosciences, Inc. (NASDAQ:ASMB) has unleashed a wave of major approvals and shifts. While accepting two amendments to the company's Amended and Restated 2018 Stock Incentive Plan (the '2018 Plan'), the stockholders elected Jeanette M. Bjorkquist as the chief financial officer. As mentioned earlier, the 2018 Plan has been amended in two distinct ways: Amendment 1 raises the number of common stock shares for issuance to 1,478,333 from 1,103,333, whereas Amendment 2 reserves an additional 225,000 shares for issuance contingent upon performance-based vesting to strengthen an extensive supplemental retention grant program. A scientist in a lab coat laboring over petri dishes and microscope in a biotechnology laboratory. During the meeting, all director nominees were appointed to serve until the 2026 annual meeting of stockholders, and in the management change, Jeanette M. Bjorkquist, the principal executive officer of Assembly Biosciences, Inc. (NASDAQ:ASMB), will also serve as the CFO. These adjustments are a testament to the company's efforts to incentivize performance and retain talent, positioning ASMB to perform well in the times ahead. Assembly Biosciences, Inc. (NASDAQ:ASMB) is a California-based biotechnology company that develops therapeutic products for treating viral diseases. Incorporated in 2005, the company collaborates with Gilead Sciences, Inc. for the research and development of virology therapies. The giant is dedicated to delivering high-quality treatments. While we acknowledge the potential of ASMB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
